Years after his death, late scientist's work could yield new cancer treatments.

The late scientist John Herr's research into the SAS1B protein has the potential to lead to new treatments for solid cancer tumors, including breast cancer, lung cancer, and melanoma. Collaborating with UVA Cancer Center's Craig L. Slingluff Jr., Herr's work suggests that selectively targeting SAS1B could have a broad and profound impact on the treatment of multiple malignancies. The protein is found on the surface of many different solid cancer cells but not on normal cells, indicating that antibody-based immunotherapy could be used to attack cancer cells while sparing healthy tissue. This research has the potential to revolutionize cancer care and provide new hope for patients with difficult-to-treat cancers. [Extracted from the article]